Multicellular resistance to tirapazamine is due to restricted extravascular transport: A pharmacokinetic/pharmacodynamic study in HT29 multicellular layer cultures

Cancer Research

Volumn 63, Issue 18, 2003, Pages 5970-5977

  Hicks, Kevin O ^a   Pruijn, Frederik B ^a   Sturman, Joanna R ^a   Denny, William A ^a   Wilson, William R ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINO 1,2,4 BENZOTRIAZINE 1 OXIDE; TIRAPAZAMINE;

ARTICLE; CALCULATION; CANCER CELL CULTURE; CELL DENSITY; CLONOGENIC ASSAY; COLON CARCINOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG METABOLISM; EXPERIMENTAL MODEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; REDUCTION;

ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG RESISTANCE, NEOPLASM; HT29 CELLS; HUMANS; MODELS, BIOLOGICAL; SPHEROIDS, CELLULAR; TRIAZINES;

EID: 0141507967     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Durand, R. E., and Sutherland, R. M. Effects of intercellular contact on repair of radiation damage. Exp. Cell Res., 71: 75-80, 1972.
2. Teicher, B. A., Herman, T. S., Holden, S. A., Wang, Y. Y., Pfeffer, M. R., Crawford, J. W., and Frei, E., III. Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science (Wash. DC), 247: 1457-1461, 1990.
3. Kobayashi, H., Man, S., Graham, C. H., Kapitain, S. J., Teicher, B. A., and Kerbel, R. S. Acquired multicellular-mediated resistance to alkylating agents in cancer. Proc. Natl. Acad. Sci. USA, 90: 3294-3298, 1993.
4. Olive, P. L., and Durand, R. E. Drug and radiation resistance in spheroids: cell contact and kinetics. Cancer Metastisis Rev., 13: 121-138, 1994.
5. Green, S. K., Frankel, A., and Kerbel, R. S. Adhesion-dependent multicellular drug resistance. Anticancer Drug Des., 14: 153-168, 1999.
6. Durand, R. E., and Olive, P. L. Resistance of tumor cells to chemo- and radiotherapy modulated by the three-dimensional architecture of solid tumors and spheroids. Methods Cell Biol., 64: 211-233, 2001.
7. St. Croix, B., Florenes, V. A., Rak, J. W., Flanagan, M., Bhattacharya, N., Slingerland, J. M., and Kerbel, R. S. Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents. Nat. Med., 2: 1204-1210, 1996.
8. St. Croix, B., Sheehan, C., Rak, J. W., Florenes, V. A., Slingerland, J. M., and Kerbel, R. S. E-cadherin-dependent growth suppression is mediated by the cyclin- dependent kinase inhibitor p27(KIP1). J. Cell Biol., 142: 557-571, 1998.
9. Kantak, S. S., and Kramer, R. H. E-cadherin regulates anchorage-independent growth and survival in oral squamous cell carcinoma cells. J. Biol. Chem., 273: 16953-16961, 1998.
10. Hague, A., Hicks, D. J., Bracey, T. S., and Paraskeva, C. Cell-cell contact and specific cytokines inhibit apoptosis of colonic epithelial cells: growth factors protect against c-myc-independent apoptosis. Br. J. Cancer, 75: 960-968, 1997.
11. Durand, R. E. The influence of microenvironmental factors during cancer therapy. In Vivo (Athens), 8: 691-702, 1994.
12. Wartenberg, M., Frey, C., Diedershagen, H., Ritgen, J., Hescheler, J., and Sauer, H. Development of an intrinsic P-glycoprotein-mediated doxorubicin resistance in quiescent cell layers of large, multicellular prostate tumor spheroids. Int. J. Cancer, 75: 855-63, 1998.
13. Tannock, I. F. Tumor physiology and drug resistance. Cancer Metastisis Rev., 20: 123-132, 2001.
14. Durand, R. E. Intermittent blood flow in solid tumours-an under-appreciated source of 'drug resistance.' Cancer Metastisis Rev., 20: 57-61, 2001.
15. Brown, J. M., and Giaccia, A. J. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res., 58: 1408-1416, 1998.
16. Zeman, E. M., Brown, J. M., Lemmon, M. J., Hirst, V. K., and Lee, W. W. SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int. J. Radiat. Oncol. Biol. Phys., 12: 1239-1242, 1986.
17. Brown, J. M. SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours. Br. J. Cancer, 67: 1163-1170, 1993.
18. Denny, W. A., and Wilson, W. R. Tirapazamine: a bioreductive anticancer drug that exploits tumour hypoxia. Expert Opin. Investig. Drugs, 9: 2889-2901, 2000.
19. Durand, R. E., and Olive, P. L. Evaluation of bioreductive drugs in multicell spheroids. Int. J. Radiat. Oncol. Biol. Phys., 22: 689-692, 1992.
20. Hicks, K. O., Fleming, Y., Siim, B. G., Koch, C. J., and Wilson, W. R. Extravascular diffusion of tirapazamine: effect of metabolic consumption assessed using the multicellular layer model. Int. J. Radiat. Oncol. Biol. Phys., 42: 641-649, 1998.
21. Phillips, R. M., Loadman, P. M., and Cronin, B. P. Evaluation of a novel in vitro assay for assessing drug penetration into avascular regions of tumours. Br. J. Cancer, 77: 2112-2119, 1998.
22. Kyle, A. H., and Minchinton, A. I. Measurement of delivery and metabolism of tirapazamine to tumour tissue using the multilayered cell culture model. Cancer Chemother. Pharmacol., 43: 213-220, 1999.
23. Mason, J. C., and Tennant, G. Heterocyclic N-oxides. Part VI. Synthesis and nuclear magnetic resonance spectra of 3-aminobenzo-1, 2, 4-triazines and their mono- and di-N-oxides. J. Chem. Soc. (B), 911-916, 1970.
24. Hicks, K. O., Ohms, S. J., van Zijl, P. L., Denny, W. A., Hunter, P. J., and Wilson. W. R. An experimental and mathematical model for the extravascular transport of a DNA intercalator in tumours. Br. J. Cancer, 76: 894-903, 1997.
25. Hicks, K. O., Pruijn, F. B., Baguley, B. C., and Wilson, W. R. Extravascular transport of the DNA intercalator and topoisomerase poison N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA): diffusion and metabolism in multicellular layers of tumor cells. J. Pharmacol. Exp. Ther., 297: 1088-1098, 2001.
26. Wilson, W. R., Pullen, S. M., Hogg, A., Hobbs, S. M., Pruijn, F. B., and Hicks, K. O. In vitro and in vivo models for evaluation of GDEPT: quantifying bystander killing in cell cultures and tumors. In: C. J. Springer (ed.), Suicide Gene Therapy: Methods and Protocols for Cancer. Totowa, NJ: Humana Press, in press, 2003.
27. Ferry, D. M., van Zijl, P. L., and Wilson, W. R. Sensitive liquid chromatographic assay for the basic DNA intercalator (N,N-dimethylaminoethyl)-9-amino-5-methylacridine-4-carboxamide and its nitroarylmethyl quaternary prodrugs in biological samples. J. Chromatogr. B Biomed. Sci. Appl., 763: 149-156, 2001.
28. Peters, K. B., and Brown, J. M. Tirapazamine: a hypoxia-activated topoisomerase II poison. Cancer Res., 62: 5248-5253, 2002.
29. Oloumi, A., MacPhail, S. H., Johnston, P. J., Banath, J. P., and Olive, P. L. Changes in subcellular distribution of topoisomerase IIα correlate with etoposide resistance in multicell spheroids and xenograft tumors. Cancer Res., 60: 5747-5753, 2000.
30. Siim, B. G., van Zijl, P. L., and Brown, J. M. Tirapazamine-induced DNA damage measured using the comet assay correlates with cytotoxicity towards hypoxic tumour cells in vitro. Br. J. Cancer, 73: 952-960, 1996.
31. Biedermann, K. A., Wang, J., Graham, R. P., and Brown, J. M. SR 4233 cytotoxicity and metabolism in DNA repair-competent and repair-deficient cell cultures. Br. J. Cancer, 63: 358-362, 1991.
32. Jones, G. D., and Weinfeld, M. Dual action of tirapazamine in the induction of DNA strand breaks. Cancer Res., 56: 1584-1590, 1996.
33. Hwang, J. T., Greenberg, M. M., Fuchs, T., and Gates, K. S. Reaction of the hypoxia-selective antitumor agent tirapazamine with a Cl′-radical in single-stranded and double-stranded DNA: the drug and its metabolites can serve as surrogates for molecular oxygen in radical- mediated DNA damage reactions. Biochemistry, 38: 14248-14255, 1999.
34. Wang, J., Biedermann, K. A., Wolf, C. R., and Brown, J. M. Metabolism of the bioreductive cytotoxin SR 4233 by tumour cells: enzymatic studies. Br. J. Cancer, 67: 321-325, 1993.
35. Patterson, A. V., Barham, H. M., Chinje, E. C., Adams, G. E., Harris, A. L., and Stratford, I. J. Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233). Br. J. Cancer, 72: 1144-1150, 1995.
36. Baker, M. A., Zeman, E. M., Hirst, V. K., and Brown, J. M. Metabolism of SR 4233 by Chinese hamster ovary cells: basis of selective hypoxic cytotoxicity. Cancer Res., 48: 5947-5952, 1988.
37. Giaccia, A. J., Biedermann, K. A., Tosto, L. M., Minchinton, A. I., Kovacs, M. S., and Brown, J. M. Characterization of a CHO cell line resistant to killing by the hypoxic cell cytotoxin SR 4233. Int. J. Radiat. Oncol. Biol. Phys., 22: 681-684, 1992.
38. Butler, J., and Hoey, B. M. The one-electron reduction potential of several substrates can be related to their reduction rates by cytochrome P-450 reductase. Biochim. Biophys. Acta, 1161: 73-78, 1993.
39. Fitzsimmons, S. A., Lewis, A. D., Riley, R. J., and Workman, P. Reduction of 3-amino-1,2,4-benzotriazine-1,4-di-N-oxide (tirapazamine, WIN 59075, SR 4233) to a DNA-damaging species: a direct role for NADPH:cytochrome P450 oxidoreductase. Carcinogenesis (Lond.), 15: 1503-1510, 1994.
40. Patterson, A. V., Saunders, M. P., Chinje, E. C., Talbot, D. C., Harris, A. L., and Stratford, I. J. Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069. Br. J. Cancer, 76: 1338-1347, 1997.
41. Evans, J. W., Yudoh, K., Delahoussaye, Y. M., and Brown, J. M. Tirapazamine is metabolized to its DNA-damaging radical by intranuclear enzymes. Cancer Res., 58: 2098-2101, 1998.
42. Daniels, J. S., and Gates, K. S. DNA cleavage by the antitumor agent 3-amino-1,2,4-benzotriazine 1,4-dioxide (SR4233): evidence for involvement of hydroxyl radical. J. Am. Chem. Soc., 118: 3380-3385, 1996.
43. Anderson, R. F., Shinde, S. S., Hay, M. P., Gamage, S. A., and Denny, W. A. Activation of 3-amino-1,2,4-benzotriazine 1,4-dioxide antitumor agents to oxidizing species following their one-electron reduction. J. Am. Chem. Soc., 125: 748-756, 2003.